XIII International AIDS Conference, Durban, South Africa, 9-14th July 2000
16 August 2000. Related: Conference reports.
Conference reports
Mother-to-child transmission, maternal health and women’s access to care
16 August 2000. Related: Conference reports, Pregnancy.
The M in MTCT: questions about HIV-positive mothers
16 August 2000. Related: Conference reports, Pregnancy.
First report of ABT-378/r use in children
16 August 2000. Related: Conference reports, Paediatric care.
Nelfinavir doses should be increased in infants less than 3 months
16 August 2000. Related: Conference reports, Paediatric care.
Metabolic and lipodystropy issues: confusion continues to reign
16 August 2000. Related: Conference reports, Side effects, Weight, diabetes, metabolic complications.
Switching studies: Can viral load be maintained and metabolic or fat redistribution significantly improved?
16 August 2000. Related: Conference reports, Side effects, Weight, diabetes, metabolic complications.
Commentary on STI talk, early entry inhibitor research, increase in viral replication seen in isolates in presence of NNRTIs
16 August 2000. Related: Conference reports.
New developments in affordable antiretroviral therapy: intermittent treatment
16 August 2000. Related: Conference reports, Treatment strategies.
Cannabinoids effect on HIV-1 viral load and appetite
16 August 2000. Related: Conference reports.
IL-2 without HAART may delay need for antiretroviral treatment
16 August 2000. Related: Conference reports.
New potential dual NNRTI-based combinations
16 August 2000. Related: Conference reports, Antiretrovirals.
Once-daily protease-based regimens
16 August 2000. Related: Conference reports, Antiretrovirals, Treatment strategies.
Mitochondrial DNA (mtDNA) damage in semen as surrogate marker for nucleoside analogue toxicity
16 August 2000. Related: Conference reports, Side effects.
Antiretrovirals and fertility – implications for couples looking to conceive
16 August 2000. Related: Conference reports.
Incidence of adverse events at 4 weeks correlates with adherence and virologic failure at 4 months
16 August 2000. Related: Conference reports, Side effects.
Prednisone and nevirapine rash
16 August 2000. Related: Conference reports, Side effects.
The prevalence of hypogonadism in HIV positive patients receiving HAART
16 August 2000. Related: Conference reports, Other news.
Human papilloma virus and HIV
16 August 2000. Related: Conference reports, Coinfections and complications.
4th International Workshop on HIV Drug Resistance and Treatment Strategies, 12-16 June 2000, Sitges, Spain
16 July 2000. Related: Conference reports.
Tenofovir (PMPA), defining cross-resistance profiles
16 July 2000. Related: Conference reports, Drug resistance.
DAPD shows activity in vitro against multidrug-resistant HIV but initial results from monotherapy in treatment experienced subjects are disappointing
16 July 2000. Related: Conference reports, Antiretrovirals.
Mycophenalate mofetil in patients with advanced disease and multidrug resistant HIV
16 July 2000. Related: Conference reports, Drug resistance.
Hydroxyurea is active in vitro against multidrug-resistant HIV
16 July 2000. Related: Conference reports, Drug resistance.
ABT-378/r (Lopinavir): defining a resistance profile and the effects of resistance on virological response in experienced patients
16 July 2000. Related: Conference reports, Drug resistance.
Indinavir/ritonavir at 400/400 mg or 800/100 mg as intensification
16 July 2000. Related: Conference reports, Antiretrovirals.
Ritonavir/saquinavir combination: effect of ritonavir dosage
16 July 2000. Related: Conference reports, Antiretrovirals.
What is the significance of blips in viral load?
16 July 2000. Related: Conference reports, Treatment strategies.
Phenotypic resistance testing improves response to therapy: final analysis of VIRA3001
16 July 2000. Related: Conference reports, Drug resistance.
A prospective study of strategic treatment interruptions in patients with chronic HIV-infection
16 July 2000. Related: Conference reports.
Added value of hydroxyurea or IL-2 to STIs remains uncertain
16 July 2000. Related: Conference reports.
Continued benefits from protease inhibitor based therapy despite virological failure
16 July 2000. Related: Conference reports, Drug resistance.
Do resistance mutations disappear off therapy?
16 July 2000. Related: Conference reports, Drug resistance.
Selection of PI mutations during slow decay of VL and resistance after PI failure
16 July 2000. Related: Conference reports, Drug resistance.
Thymidine analogues mutations (TAMS) and other NA-related resistance mutations
16 July 2000. Related: Conference reports, Drug resistance.
Nevirapine vs efavirenz: the SENC trial
16 July 2000. Related: Conference reports, Antiretrovirals.
A warning on simplification strategies: not suitable for all
16 July 2000. Related: Conference reports.
Third International Workshop on Salvage Therapy for HIV Infection, April 12-14, 2000, Chicago, USA
16 June 2000. Related: Conference reports.
Exercise testing in HIV patients with random increased lactic acid levels: evidence for a reduced anaerobic threshold with a pattern of mitochondrial dysfunction
15 June 2000. Related: Conference reports, Side effects.
Third International Workshop on Salvage Therapy for HIV Infection, April 12-14, 2000, Chicago, USA
15 May 2000. Related: Conference reports.
Clinical studies of indinavir/ritonavir as salvage therapy
15 May 2000. Related: Conference reports, Drug resistance.
Indinavir plus ritonavir: might exposure to higher levels of indinavir overcome protease resistant HIV and prove useful to ‘rescue’ previously failed protease inhibitor based combinations?
15 May 2000. Related: Conference reports, Drug resistance.
First International Workshop in Clinical Pharmacology in HIV Therapy, 30-31 March 2000, Noordwijk, Netherlands
15 May 2000. Related: Conference reports.
TDM: standardisation and quality control
15 May 2000. Related: Conference reports.
TDM in clinical practice
15 May 2000. Related: Conference reports.
ATHENA – Early results from first randomised study of clinical benefits of TDM
15 May 2000. Related: Conference reports.
TDM for individualising dosing – practicality and efficacy for PIs and RTIs
15 May 2000. Related: Conference reports.
TDM and adherence
15 May 2000. Related: Conference reports.
Drug interactions: amprenavir, saquinavir, ABT-378/r (lopinavir/r), indinavir, efavirenz, ritonavir
15 May 2000. Related: Conference reports, PK and drug interactions.
L-Acetyl Carnitine (LAC) improves symptoms of peripheral neuropathy (PN): evidence for increases in cutaneous innervation
15 May 2000. Related: Conference reports, Side effects.
7th Conference on Retroviruses and Opportunistic Infections (ROI), January 30-February 2 2000, San Francisco
14 April 2000. Related: Conference reports.
Paediatrics: children are not small (or miniature) adults
14 April 2000. Related: Conference reports, Paediatric care.
HIV-positive women, pregnancy and newborns
14 April 2000. Related: Conference reports, Pregnancy, Drug resistance.
Flu-like symptoms of severe acute HIV infection develop after suspension of HAART
14 April 2000. Related: Conference reports.
Non-clade B virus: epidemiology, testing strategies and resistance
14 April 2000. Related: Conference reports, Drug resistance.